Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,565 Million (Mid Cap)
20.00
NA
2.65%
-0.29
10.12%
1.81
Revenue and Profits:
Net Sales:
251 Million
(Quarterly Results - Sep 2025)
Net Profit:
117 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.77%
0%
0.77%
6 Months
-10.75%
0%
-10.75%
1 Year
7.06%
0%
7.06%
2 Years
-4.65%
0%
-4.65%
3 Years
-44.83%
0%
-44.83%
4 Years
-43.09%
0%
-43.09%
5 Years
-59.43%
0%
-59.43%
Wuhan Keqian Biology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.94%
EBIT Growth (5y)
1.30%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.31
Sales to Capital Employed (avg)
0.25
Tax Ratio
13.25%
Dividend Payout Ratio
52.17%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
22.33%
ROE (avg)
12.82%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
2.01
EV to EBIT
16.08
EV to EBITDA
12.47
EV to Capital Employed
2.95
EV to Sales
6.09
PEG Ratio
0.57
Dividend Yield
2.45%
ROCE (Latest)
18.32%
ROE (Latest)
10.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
250.60
240.50
4.20%
Operating Profit (PBDIT) excl Other Income
114.40
125.50
-8.84%
Interest
0.10
0.10
Exceptional Items
14.40
8.60
67.44%
Consolidate Net Profit
117.30
111.50
5.20%
Operating Profit Margin (Excl OI)
456.40%
404.10%
5.23%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 4.20% vs -1.27% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 5.20% vs 3.43% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
938.50
1,057.20
-11.23%
Operating Profit (PBDIT) excl Other Income
417.50
468.50
-10.89%
Interest
5.00
8.30
-39.76%
Exceptional Items
27.30
-6.90
495.65%
Consolidate Net Profit
381.50
395.60
-3.56%
Operating Profit Margin (Excl OI)
327.90%
334.90%
-0.70%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -11.23% vs 6.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -3.56% vs -3.30% in Dec 2023
About Wuhan Keqian Biology Co., Ltd. 
Wuhan Keqian Biology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






